Notice of Pre-AIA or AIA Status
The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA .
DETAILED ACTION
This is a response to Applicant’s communication filed on September 14, 2026. Application No. 18/832,088, is a 371 of PCT/US2023/061185, filed January 24, 2023, and claims the benefit of U.S. Provisional application No. 63/302,942, filed January 25, 2022. In a preliminary amendment filed March 18, 2025, Applicant cancelled claims 3-7, 11-15, 17-28, 30, 32-40, 42-44, and 54-56. Claims 1, 2, 8-10, 16, 29, 31, 41, 45-53, 57 and 58 are pending.
Election/Restrictions
Applicant’s election without traverse of the invention of Group I and the species of Compound No. 1011, in the reply filed on September 14, 2026, is acknowledged. Claims 47-53, 57, and 58 are withdrawn from further consideration pursuant to 37 CFR 1.142(b) as being drawn to a nonelected invention. Claim 45 is withdrawn from further consideration pursuant to 37 CFR 1.142(b) as being drawn to a nonelected species. The election was made without traverse in the reply filed on September 14, 2026.
Claims 1, 2, 8-10, 16, 29, 31, 41, and 46 are examined below.
Claim Rejections - 35 USC § 102(a)(1)
The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:
A person shall be entitled to a patent unless –
(a)(1) the claimed invention was patented, described in a printed publication, or in public use, on sale, or otherwise available to the public before the effective filing date of the claimed invention.
Claims 1, 31 and 46 are rejected under 35 U.S.C. 102(a)(1) as being anticipated by Wiles et al., US2020/0071301 A1. The CAS abstract for Wiles discloses the following compound:
PNG
media_image1.png
267
454
media_image1.png
Greyscale
(Wiles et al., citing the CAS abstract for the compound depicted above; see Wiles et al., US PG ‘301 publc’n, Abstract for pharmaceutical compositions of the compounds disclosed therein.) This compounds reads on a compound of formula (I), wherein formula (I), A is a pyrimidyl, n = 1, R3 is methyl; R2 is hydrogen; R1 is C(O)N(CH3)OCH3; X1 is CH; X2 is N; and R6 is H.
Conclusion
Claims 1, 31 and 46 are not allowed.
Claims 2, 8-10, 16, 29, and 41 are objected to as being dependent upon a rejected base claim, but would be allowable if rewritten in independent form including all of the limitations of the base claim and any intervening claims.
Contact Information
Any inquiry concerning this communication or earlier communications from the examiner should be directed to TIMOTHY R ROZOF whose telephone number is (571)270-5992. The examiner can normally be reached on Monday - Friday, 9:00 a.m. -5:00 p.m..
If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Andrew Kosar can be reached on (571) 272-0913. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.
Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.
/TIMOTHY R ROZOF/
Primary Examiner, Art Unit 1625
Prosecution Insights